Thomas F. Isett III
Net Worth

Last updated: 29 Oct 2019

What is Thomas F. Isett III net worth?

The estimated net worth of Mr. Thomas F. Isett III is at least $8,055,500 as of 29 Oct 2019. He owns shares worth $255,500 as insider and has received compensation worth at least $7,800,000 in iBio, Inc..

What is the salary of Thomas F. Isett III?

Mr. Thomas F. Isett III salary is $1,300,000 per year as Chief Executive Officer, Pres & Chairman in iBio, Inc..

How old is Thomas F. Isett III?

Mr. Thomas F. Isett III is 60 years old, born in 1965.

What stocks does Thomas F. Isett III currently own?

As insider, Mr. Thomas F. Isett III owns shares in one company:

Company	Title	Shares	Price per share	Total value
iBio, Inc. (IBIO)	Chief Executive Officer, Pres & Chairman	350,000	$0.73	$255,500

What does iBio, Inc. do?

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.